Member Info for Burble

For those of us who weren't able to attend the AGM yesterday. The presentation that was given is now live on the Scancell website. https://www.scancell.co.uk/Data/Sites/1/media/docspres/agm-presentation2021.pdf

'New avidimab could be huge' - can anyone shed light on the word 'new'. Is this a new version of avidimab or is this the same as before?

C7

That’s fantastic news! A nice thing to wake upto on a wet Wednesday morning!

Thanks Bob, that’s really helpful to read. Would love to have been a fly on the wall in the Avidimab meetings. Wonder what was offend and turned down and by who?

When you say new Avidimab - can you expand? Does this mean we have Avidimab 2.0?

Agree! This is why I wish they had done it as a hybrid model. That way all shareholders could listen in and hear what LD and the team have to say rather than just trying to decipher from a presentation afterwards.

However statistically 6 out of 7 dwarves are not happy.

I forgot to email my question through to the BOD. But if someone is attending the AGM tomorrow and gets the chance to ask a question - are you able to ask the following?

'Is the BOD in a position to confirm whether we did or did not submit an application to CEPI for their funding call regarding variant resistant beta-coronavirus vaccines?'

Would be helpful to know whether or not we should be holding out hope with CEPI or whether this card isn't on the table.

Good luck today C7, I hope it goes smoothly.

Am I right in thinking that the AGM is not being conducted in a hybrid manner? If so, it’s mildly disappointing after two years of pandemic that this wasn’t considered an option to allow more of us shareholders to attend virtually. Happy to be corrected if I’m wrong - if I am, can somebody point me to where I can find login details!

It’s really positive for SCLP and patients alike. A long time coming and hopefully we will see a full cohort recruited relatively smoothly and quickly.

Also I get the sense that Covid stocks have waned in favour, so hopefully people realise Scancell aren’t a one trick pony.

Instead they are a really exciting Biotech with many diverse strings to their bow across multiple platforms targeting infectious diseases and cancer.

LL you’re not the only one who had noticed this, I suspect though that part of it may stem from the fact that we are flying under the radar for a lot of people and are trading in an almost horizontal line.

I suspect any day traders and people after a quick buck may be wanting a rise as they have funds caught up here. For us LTH I just ignore the intraday chatter, may research some other competitors but end up coming back here as after over a decade of holding I’m not going anywhere soon.

Have just emailed the author Julia highlighting Scancell, that we are already in clinical trials and also highlighting that Modi-1 FPD should be announced soon. We shall see how much traction this gets. Once FPD comes back or interim results are released for Covidity, I'll ping her an email back and give her a nudge.

Does anyone else think that the watered down COP26 agreement on coal play into our hands? Especially if management could pull their finger out and get facilities up and running quicker.

Balerno

Ethics in the UK are done through the Health Research Authority (HRA) via the Integrated Research Application system (IRAS). Applications for clinical trials use IRAS to send the application to both the MHRA (who deal with the technicalities of the trial and scientific data) before it goes to a HRA ethics committee for ethical approval.

An ethics committee aims to give an opinion within sixty days of receipt of an application, though this depends whether there are any queries or issues raised.

A submission to the HRA can Either go to a nominated ethics committee in which case it will be heard at the next available meeting slot or it can go to any ethics committee - this is usually quicker but some people prefer to use their local one for convenience.

Once an ethical opinion is given, if this is conditional, then the research has to go away, do the edits to the documentation, before resubmitting it to the REC for sign off. Usually for minor issues raised at ethics these can be done between meetings, if issues raised are major then the applicant may be asked to resubmit to the ethics committee before a verdict can be given.

Stipend would suggest a PhD student.

A really interesting publication - it also highlights how important the patent landscape is for Scancell and the whole moditope platform. It's not as simple as just running some sequences through an algorithm and then using those in mice. There is some real skill in identifying which combinations work and how - all of which feeds in to further patents for moditope.

You and me both! Sadly I can't justify a round trip to London at this current moment in time as other life pressures take preference. Would be nice if it could be a hybrid event.

JB1

Yes you’re correct, Modi-1 and I think all the Scancell platforms (Immunobody and Moditope platforms) are patient agnostic meaning reduction in costs in manufacture, storage and delivery. So will be interesting to see results from this vs the other one you mentioned. It also means relatively swift patient enrolment because you don’t have to make the therapeutic on a bespoke patient by patient basis.

Got a lovely response from the author of that Telegraph article saying he would look into SCLP in more detail especially as the cancer vaccine sector was hotting up. Another journalist with us on the radar can’t do any harm!

When Modi-1 gets approved and FPD I’ll ping him another line to give him a nudge.

Just dropped the author an email. Five minutes of my time and no harm done. Especially if there are other news items which are soon to drop - Modi-1 trial start would be a good one if SCLP is on his radar.

Question - do we know for sure whether SCLP have applied to CEPI? Or are we just putting two and two together based on the fact CEPI have tweeted about us before?